Today’s New York Times provides arguments from drug companies justifying the excessive jump in pharmaceutical prices in recent years, saying the higher prices won’t impact patients. 

Hospitals’ top priority is providing patients with safe and effective care, but the skyrocketing costs of pharmaceuticals can make doing so difficult. The high cost of prescription drugs leads to higher out-of-pocket costs for patients, who then may not be able to afford their medications. This may cause them to require further health care interventions – interventions that would have been avoidable if they had been able to take the original prescription. Indeed, these prices are putting a strain on the entire health care system – the drug companies’ statement that they only hurt a hospital’s bottom line is pure fantasy.

And patients aren’t the only ones suffering the effects of the higher prices -- taxpayers are also hurt. Because of the way Medicare pays for many drugs, increasing the base price means higher costs to the Medicare program.

Hospitals have worked hard to hold costs down. The same should be expected from the drug sector. The only ones who benefit from these unsustainable drug prices are pharmaceutical companies and their shareholders.

Related News Articles

Headline
Ways and Means Committee Chairman Richard Neal, D-Mass., and Energy and Commerce Committee Chairman Frank Pallone Jr., D-N.J., along with Ranking Members Kevin…
Headline
An estimated 23.6 million Americans with employer-based health coverage spent at least 10 percent of their 2016-2017 income on premiums or out-of-pocket…
Headline
Leaders of the Senate Committee on Health, Education, Labor and Pensions today released the Lower Health Care Costs Act of 2019 – bipartisan discussion draft…
Headline
The Fifth Circuit Court of Appeals said today that it will hear oral arguments July 9 in the appeal of a district court decision that struck down t
Headline
Tax-exempt hospitals and health systems provided $95 billion in community benefits in 2016, almost 11 times the value of their federal tax exemption.
Headline
The House Energy and Commerce Subcommittee on Health today held a hearing on seven bills aimed at improving transparency in the drug supply chain to lower…